Advantage of Antibody-Based Selectivity
in the Purification of Next-Generation Biologics
This webcast has passed. You can now watch the recording at any time: Click here.
Presenter:
Laurens SierkstraSenior Director, Business Leader Purification,
Thermo Fisher Scientific
Laurens received his PhD in biotechnology in 1994 from the University of Utrecht after studying biology at the University of Leiden. He then joined Unilever as Project Manager and Unit Leader. In 2005, after the spinout of BAC BV from Unilever, he became CEO of BAC BV and set up the business in using single- domain antibodies for affinity purification, called CaptureSelect, which was sold in 2013 to Life Technologies. Since the acquisition by Thermo Fisher Scientific, he has been the business leader for the affinity purification business within the Bioproduction Division
